Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
Fiche publication
Date publication
juillet 2017
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle, Dr DEBIEUVRE Didier
Tous les auteurs :
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M,
Lien Pubmed
Résumé
EGFR mutations cause inconsistent response to EGFR tyrosine kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR -mutated NSCLC collected in the Biomarkers France database.
Mots clés
epidemiology, epidermal growth factor receptor gene (EGFR) mutations, non-small-cell lung cancer (NSCLC), tyrosine-kinase inhibitors (TKI)
Référence
Ann. Oncol.. 2017 Jul;: